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Costing juvenile idiopathic arthritis: examining patient-based costs
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Objectives. There are few data on the treatment patterns and associated cost of treating children with inflammatory arthritis including juvenile
idiopathic arthritis (JIA), in the short or long term. The aim of this study was to obtain patient-based costs for treating children with JIA in the
UK, in the first year from diagnosis and from the secondary health care payer perspective.
Methods. The Childhood Arthritis Prospective Study (CAPS) is an ongoing longitudinal study recruiting children with inflammatory arthritis
from four UK hospital centres. Included children are newly diagnosed, 16 years old with inflammatory arthritis of one or more joints, which
has persisted for at least 2 weeks. Health service resource use data were collected as part of routine clinical care at study entry, 6 months and
1 year. Reference unit costs were applied to these data and the cost of treatment per child calculated for the first year from diagnosis.
Results. A total of 297 children attended a 12-month follow-up visit. The mean annual total cost per child was £1649 (S.D. £1093, range
£401–£6967). The highest cost component was for appointments with paediatric rheumatologists. Mean total costs were highest for children
with enthesitis-related, systemic JIA or extended oligoarthritis.
Conclusions. In the first 12 months after diagnosis, children with all JIA disease subtypes consume large, but highly variable quantities of
health service resources. Individual patient costs are required to reflect the wide variation in cost between patients and allow appropriate
recouping of costs for contracted services and for assessing the economic impact of interventions.
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Introduction
Juvenile idiopathic arthritis (JIA) is a debilitating chronic disease
in children. Early, intensive, multi-disciplinary management is
needed to reduce joint and other damage from the disease and
achieve the best outcomes for these children [1]. Chronic treatment
into adulthood is often necessary, placing a long-term economic
burden on health care providers. However, many bodies with
purchasing responsibility have limited knowledge of the costs of
treating such patients. Recent pharmaceutical advances, such as
anti-TNF therapy, may be useful for improving the health of these
children but are associated with increased costs [2]. Individual
patient cost data are required to assess the economic impact of
these interventions. There are few data on the cost of treating
children with JIA. Seven studies have reported costs of manage-
ment and suggest a substantial economic impact but do not
provide sufficient data to describe the long-term resource use
requirements of children with the different subtypes of JIA [2–8].
Therefore, the aim of this study was to obtain accurate patient-
based costs for the cost of treating children with JIA in the UK,
in the first year after diagnosis.
Patients and methods
The patients
The Childhood Arthritis Prospective Study (CAPS) is an ongoing
UK longitudinal study conducted by the Arthritis Research
Campaign (ARC) Epidemiology Unit, the University of
Manchester. The aim of CAPS is to identify predictors of
outcome, both short- and long-term, following presentation with
childhood-onset inflammatory arthritis and to identify the rela-
tive contributions of socio-demographic, clinical, psychological,
laboratory and genetic factors in explaining outcome. In total,
children are recruited from five paediatric rheumatology centres;
this analysis used data from four centres (Booth Hall Children’s
Hospital in Manchester, Royal Liverpool Children’s Hospital,
Royal Victoria Infirmary in Newcastle and Royal Hospital for
Sick Children in Glasgow). The inclusion criteria are children 16
years old with newly-diagnosed inflammatory arthritis of one or
more joints, which has persisted for at least 2 weeks. JIA is
subsequently classified according to the ILAR criteria [9–11].
Exclusion criteria include arthritis subsequently diagnosed to be
caused by infection, trauma, foreign body or haematological/
oncological conditions, and connective tissue disorders. Data are
collected as part of routine clinical care at first presentation and
study entry (baseline), 6 months and at 1–5 years. At each time-
point, children undergo a rheumatological examination by the
consultant, a comprehensive case notes review is undertaken and
the nurse completes an assessment form together with the child
and parents.
Design of costing study
This costing study aimed to describe the resource use and
associated costs in children with JIA recruited to CAPS, from
the perspective of the secondary care provider. Although CAPS
data were collected as a study examining outcomes, the database
also provided detailed information on NHS treatment patterns.
The categories of resource use obtained from the CAPS database
were: consultant paediatric rheumatologist appointments and
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referrals to other specialists or care; medication for inflammatory
arthritis; laboratory investigations and clinical imaging; and
surgery.
Consultant paediatric rheumatologist appointments and
referrals to other specialists or care. The number of appoint-
ments with paediatric rheumatologists during the follow-up period
was recorded for each child. The database recorded routine
referrals to ophthalmologists, specialist paediatric rheumatology
nurses, physiotherapists, occupational therapists, podiatrists, and
requirements for splinting and orthotics. However, the number
of appointments with each specialist was not recorded, so these
data were estimated based on known treatment approaches,
or through consultation with relevant health care providers
(Table 1). National and local reference unit costs (using the
mean cost) were attached to the resource use data.
Medication for JIA. Type of medication prescribed was
recorded on CAPS but not doses. The recommended doses
of drugs were taken from the British National Formulary for
Children [12] and the British National Formulary [13], December
2005, as appropriate; consultation with paediatric rheumatologists
ensured that they reflected local practice. Individual doses were
then calculated for each child in the study from the weight (kg)
and age of each child. For MTX dosage, body surface area (BSA)
was calculated from height and weight using the equation of
Mosteller: BSA¼ˇ[height (cm)weight (kg)/3600] [14, 15].
Where heights and weights were missing for follow-up visits,
regression of the weights from all children estimated a mean
increase in weight or height per child per year, which was added
to the baseline value to supply a missing follow-up value. For
children in whom weight or height was not recorded either at
baseline or follow-up, the weights were applied from national
children’s mean values recorded in the Health Survey for England
(http://www.ic.nhs.uk/pubs/hlthsvyeng2004upd). The duration
of treatment for each drug for each child was calculated from
the recorded dates of starting and stopping treatment for each
follow-up visit.
The costs of drugs were obtained from the British National
Formulary for Children [12] and the British National Formulary
[13], December 2005. Costs of generic drugs were used through-
out. For drugs where different strength tablets were available, the
cost of the lowest strength tablet was used to calculate the total
cost. Where drugs were available as liquid formulation or tablets,
it was assumed that children aged <12 years old would receive
syrup, suspension or soluble tablets whereas older children would
be able to take tablets. For calculating the cost of eye drops, it was
assumed that there were 200 drops in one 10ml bottle and that
patients would need two drops twice a day in both eyes and the
bottle would have a 28-day expiry.
For IA corticosteroid injections, it was expected that all
children treated were booked into the hospital on a day-case
basis. After discussion with the paediatric rheumatologists, a
general guideline was applied, in that children under 8 years old
TABLE 1. Unit costs of appointments with health care professionals
Number of sessions:
actual or estimated Source Cost (£)
Appointment/referral
Paediatric rheumatologist
appointment
CAPS database Department of Health Reference Costs 2004
Paediatric clinic follow-up appointment
133.00
Ophthalmologist appointment 2 Department of Health Reference Costs 2004
Adult follow-up appointment
55.00
Specialist nurse visit 3 Personal Social Services Research Unit Costs of Health and Social Care 2005
Half an hour of patient contact
16.50
Physiotherapist visit 6 Personal Social Services Research Unit Costs of Health and Social Care 2005
Half an hour of patient contact
21.00
Occupational therapy 2 Personal Social Services Research Unit Costs of Health and Social Care 2005
Half an hour of patient contact
22.50
Splinting 2 Personal Social Services Research Unit Costs of Health and Social Care 2005
Half an hour of patient contact
22.50
Podiatry 3 Department of Health Reference Costs 2004
Adult follow-up appointment
45.00
Orthotics 3 Department of Health Reference Costs 2004
Adult follow-up appointment
Used podiatry costs.
45.00
Dietician visit 1 Personal Social Services Research Unit Costs of Health and Social Care 2005
Half an hour of patient contact
17.50
Endocrinologist appointment 1 Department of Health Reference Costs 2004
Adult follow-up appointment
121.00
Dermatologist appointment 1 Department of Health Reference Costs 2004
Adult follow-up appointment
62.00
Cardiologist appointment 1 Department of Health Reference Costs 2004
Adult follow-up appointment
95.00
Psychologist appointment 1 Personal Social Services Research Unit Costs of Health and Social Care 2005
Half an hour of patient contact
38.50
Hydrotherapya 24 Personal Social Services Research Unit Costs of Health and Social Care
2005, Epps et al. [3]
61.10
Investigations/laboratory tests
Blood and biochemistry CAPS database Department of Health Reference Costs 2004 Haematology 32.28
Immunology 8.16
Biochemistry 1.88
Other 8.44
X-rays CAPS database Local costs 195.92
MRI CAPS database Department of Health Reference Costs 2004 224.00
Ultrasound CAPS database Department of Health Reference Costs 2004 32.00
Bone scan CAPS database Department of Health Reference Costs 2004 142.00
Sources of data: Department of Health Reference Costs 2004 (www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/NHSReferenceCosts/fs/en). Personal Social Services
Research Unit Costs of Health and Social Care 2005, University of Kent [17]. aBased on information and data in a study of hydrotherapy in children with JIA [3]. Two physiotherapists were needed for an
appointment lasting 29 min. The costs for the physiotherapists were taken from the PSSR Unit Costs of Health and Social Care 2005, per hour of patient contact. The fixed costs of a hydrotherapy
appointment were obtained from Epps et al. and inflated to 2005 costs using Hospital and Community Health services pay and price inflation [17]. Fixed costs and staff costs were added to give the
total cost.
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would need a general anaesthetic but older children could have
nitrous oxide, although in practice this would vary depending on
the number of joints to be treated and the individual child. The
cost of an episode of day-case surgery for children was obtained
from a previous study [16]. The mean total cost per child per
surgical incident was £89.30 for year 2000 and was inflated to 2005
costs [17]. Only this single cost was available for day-case surgery
in children and so it was assumed that there was no difference in
cost used for children having general anaesthetic or nitrous oxide.
As children would only require one session of anaesthesia
regardless of the number of injections required, the analysis
assumed a single injection for a large joint, in a single anaesthetic
session. The cost of day-case surgery was added to the cost of the
corticosteroid injection in the analysis.
Laboratory investigations and clinical imaging. Resource
data for haemaglobin, platelets, white blood cell count, lympho-
cyte count, neutrophils, ESR, CRP, ANA, B27 and immuno-
globulin estimation were collected. Referral for clinical imaging
procedures (X-ray, ultrasound, MRI and bone scans) was
recorded. As it is unlikely that many children would have had
more than one of each imaging procedure in each follow-up
period, it was assumed that they had just one investigation. Mean
costs per test were taken from the NHS Reference Costs 2004.
None of the reference costs were specific to children. The local
cost for X-rays in children from Booth Hall Children’s Hospital,
Manchester was used as these costs were not available elsewhere.
Surgery. Referrals for surgery were also collected but by
12 months, none were JIA related.
Cost analysis. Costs of appointments and referrals, drug
treatment, laboratory tests, clinical imaging and total costs were
estimated for all patients who remained in the study for 1 year.
Analysis was undertaken using STATA version 8.
The objective of the statistical analysis was to test whether there
were statistically significant differences in costs between JIA
subtypes. The small sample size in this study, with a highly skewed
distribution, indicated non-normality. Standard parametric-based
approaches would not be robust and non-parametric statistical
tests were considered inappropriate because they do not test
differences in arithmetic means [18, 19]. The arithmetic mean is
considered to be the most relevant measure for health care policy
decisions, which should be based on information about the
distribution of the costs of treatment as well as the average cost.
Data transformation to achieve approximate normality does not
result in a comparison of arithmetic means. Therefore, non-
parametric bootstrapping was used to compare arithmetic means
of cost data [19]. Analysis of variance (ANOVA) was applied to
the data generated by bootstrapping (using Excel), for multiple
group comparisons.
Research ethics committee approval. CAPS was approved
by the North West Multicentre Research Ethics Committee.
Parent(s) or guardians were given an information sheet and
children an age-adjusted information sheet. Parent(s)/guardians
provided informed consent for recruitment and children, if
considered able, provided consent.
Results
At the time of analysis, 358 children were expected to have
attended both a baseline visit and a 12-month follow-up visit. One
year of data were available for 297 of these children; the remaining
children who did not attend the 12-month appointment included
non-attenders, those who had moved provider or those in whom
JIA had resolved. For the purpose of this analysis, these children
have not been included. However, although children who were
lost to follow-up were slightly older than those who were included
in the analysis (9.2 and 7.9 years, respectively), distributions of sex
and ILAR subtype were similar between the two groups.
Table 2 summarizes baseline characteristics, total costs and cost
of each component of care. For all children with inflammatory
arthritis, the mean annual total cost of management per child was
£1649 (S.D. £1093, range £401–£6967), which equates to US$ 3347
(2219, 814–1423) and 2391 euros (1585, 581–10 102) (source:
Reuters). The distribution of total costs for the children was
truncated with a highly skewed distribution, indicating non-
normality (Fig. 1).
The 297 children had a total of 1658 appointments with
paediatric rheumatologists during the 1-yr study period, in
addition to 2094 appointments with physiotherapists (including
hydrotherapy), 798 with ophthalmologists for screening and
management of uveitis, 438 with specialist rheumatology nurses,
192 with occupational therapists and 180 with podiatrists. The
cost of appointments with paediatric rheumatologists comprised
the major portion of the cost of management for each of the JIA
subtypes and overall (Table 1) (Fig. 2).
Statistically significant differences in total costs were found
between nearly all of the disease subtypes [ANOVA: F(8, 1882.47);
P< 0.0001; Tukey’s honest significance difference test, P< 0.0001]
(Fig. 2). Mean (S.D.) total costs were highest for children with
enthesitis-related arthritis £1981 (£1395), P< 0.01. The costs of
managing systemic JIA £1929 (£925) and extended oligoarthritis
£1912 (£730) were not significantly different from one another.
Costs for all other JIA subtypes were significantly different from
one another (P< 0.01).
Discussion
This cohort study demonstrated that, in the first 12 months after
diagnosis, children with inflammatory arthritis consume large, but
highly variable quantities of health service resources. It is not
known whether this consumption pattern persists for individual
patients as their disease progresses beyond the first year from
diagnosis. The largest component of health provider costs was
consultant rheumatology appointments, followed in order of
magnitude by referrals to other specialists, clinical imaging, drugs
and laboratory tests. The right-skewed distribution of costs
suggests that a few high-cost outliers increased the mean costs
for the group overall, and within individual disease subgroups
[18, 19]. This is a typical pattern for cost data. These data also
appear to suggest that different disease subgroups may be
associated with different levels of resource consumption. For
example, the higher costs for enthesitis-related arthritis appear to
be a result of an increased need for imaging. Bernatsky et al. [8]
also found that systemic and polyarthritis JIA subtypes predicted
higher cost of treatment compared with the other subtypes.
However, numbers in some of the subgroups were very small in
our study. Data from a larger cohort, over a longer period of time
are required to further substantiate these results. For this analysis,
children were allocated into the categories early on in the disease
course and the classification of the child can be changed with time;
it would be expected that some children would move from the
oligoarthritis category into the extended oligoarthritis category.
There were limitations of our analysis. The CAPS study
database was not designed to reflect all NHS contact and the
routine data may not be identifying all the interventions involved,
so we had to make informed assumptions about treatment from
the data that were available. For example, the length and number
of appointments was estimated, dose of drugs estimated, one
session of general anaesthetic was assumed to be sufficient for any
number of joint injections and we assumed only one clinical X-ray
image per follow-up and we had limited data on inpatient
management. Thus, it is likely that our costs are conservative
estimates of the true costs. Data collection can be refined for
future analyses. Furthermore, anecdotal evidence suggests that
costs of interventions such as joint injections and MRI scans can
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vary hugely between individual children, such that our costs
underestimate true variability. It was not possible to calculate the
loss to follow-up because the reasons for non-attendance are not
clear yet. It may be that patients with milder disease are lost from
the database because of resolution of disease, such that our data
reflects more of the severely ill children only, thus overestimating
the costs. However, children may have persisting disease but may
have moved to a different geographical area. There are no data on
resource use before the child reaches paediatric rheumatology
care; retrospective data collection may be needed to better
understand the range and quantity of testing carried out in
children with suspected JIA. Furthermore, this study does not
provide information on the cost of JIA in primary care or the
wider impact on personal social services. Despite these limitations,
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FIG. 1. Distribution of individual total costs of management of children with JIA for the first year after diagnosis.
TABLE 2. Baseline characteristics and 1-yr costs of treatment after diagnosis of JIA
All Systemic Oligoarthritis
Extended
oligoarthritis
Polyarthritis
RF-negative
Polyarthritis
RF-positive
Enthesitis-
related
arthritis
Psoriatic
arthritis Undifferentiateda
Other
inflammatory
arthritisb
N 297 17 139 17 41 9 24 17 12 17
Male/female 106/191 2/15 45/94 6/11 7/34 1/8 2/22 5/17 6/6 9/8
Age at baseline
in years,
mean (S.D.)
8.2 (4.3) 7.8 (4.0) 7.3 (4.3) 5.8 (3.7) 8.0 (3.7) 13.8 (2.8) 12.3 (2.3) 9.9 (4.5) 8.4 (4.3) 8.2 (4.1)
Cost of treatment: mean cost per child (S.D.) and range
Consultant paediatric
rheumatologist
appointments
£742 (479)
266–3990
£1072 (780)
399–3591
£689 (398)
266–3325
£782 (420)
399–1862
£834 (379)
399–1862
£680 (458)
399–1862
£848 (611)
399–3192
£563 (197)
266–1064
£964 (980)
399–3990
£579 (282)
399–1463
Referrals to other
specialists/care
£385 (332)
0–1954
£262 (399)
0–1592
£365 (271)
0–1122
£594 (385)
126–1702
£511 (416)
0–1938
£494 (301)
126–978
£357 (435)
0–1954
£352 (215)
0–700
£240 (326)
0–1032
£321 (291)
0–992
Clinical imaging £309 (861)
0–5345
£227 (249)
0–1035
£350 (1019)
0–5345
£142 (192)
0–708
£291 (828)
0–5345
£125 (160)
0–392
£483 (1097)
0–4198
£118 (155)
0–452
£421 (493)
0–1278
£305 (906)
0–3781
Laboratory tests:
blood and
biochemistry
£37 (32)
0–277
£49 (58)
0–223
£30 (21)
0–98
£58 (39)
12–154
£44 (25)
7–121
£62 (20)
30–92
£44 (53)
0–277
£37 (21)
7–65
£24 (23)
0–63
£27 (24)
0–78
Drugs £175 (272)
0–2705
£319 (383)
16–1288
£144 (168)
0–1122
£336 (498)
0–2073
£163 (142)
0–622
£248 (410)
0–1288
£253 (569)
0–2704
£147 (132)
0–2704
£128 (217)
0–780
£62 (86)
0–262
Total cost £c £1649 (1093)
401–6967
£1929 (925)
560–4053
£1579 (1163)
490–6967
£1912 (730)
686–3368
£1843 (982)
867–6519
£1608 (740)
875–2745
£1981 (1395)
730–5003
£1217 (369)
791–2260
£1778 (1478)
702–6032
£1290 (958)
401–4324
Total cost US$ 3347 (2219)
814–1423
3916 (1878)
1137–8228
3205 (2361)
995–14 143
3881 (1482)
1393–6837
3741 (1993)
1760–13 234
3264 (1502)
1776–5572
4021 (2832)
1482–10 156
2471 (749)
1606–4588
3609 (3000)
1425–12245
2619 (1945)
814–8778
Total cost in euros 2391 (1585)
581–10, 102
2797 (1341)
812–5877
2290 (1686)
711–10 102
2772 (1059)
995–4884
2672 (1424)
1257–9453
2332 (1073)
1268–3980
2872 (2023)
1059–7254
1765 (535)
1147–3277
2578 (2143)
1018–8746
1871 (1389)
581–6139
a Failure of diagnosis to comply with one of the other JIA subtypes or because of the fulfilment of more than one set of criteria. bInflammatory arthritis but not classifiable as JIA. cANOVA: F (8, 1882.47);
P< 0.0001; Tukey’s honest significance difference test, P< 0.0001. All cost groups are significantly different at P< 0.01 level, except for systemic arthritis and extended oligoarthritis.
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these data provide a valuable insight into the management of
children with JIA during the first year from diagnosis. This is the
first time longitudinal treatment practice and cost data have been
assessed in this disease group, presenting essential information for
contracting and research purposes.
A review of the published literature confirmed the lack of data
on the cost of treating children with JIA [2–8]. Only two previous
studies were relevant to the UK healthcare perspective [2, 3].
Cummins et al. [2] undertook a health technology assessment of
etanercept in JIA, from a UK perspective. The authors adapted an
adult cost–utility model for evaluating the outcomes and costs of
treatment and had to make many assumptions in order to apply
it to children. In a UK 6-month randomized controlled trial,
Epps et al. [3] compared the costs of standard physiotherapy
with physiotherapy plus hydrotherapy in children with JIA for
>3 months. All treatment costs from the perspectives of the NHS
and the children’s families were included. The most recent and
comprehensive study was conducted from the Canadian health-
care perspective [8]. Bernatsky et al. [8] estimated the mean direct
medical costs for children with JIA as Canadian $3002 compared
with $1315 for outpatient control children without chronic
disease. The higher cost for children with JIA was mainly because
of higher drug costs although these children also had higher costs
related to appointments with healthcare professionals and
diagnostic tests. One study evaluated the costs of 3 and 12
months of treatment in the United States [5]. The mean annualized
direct cost per child was $7905 (inpatient, $1717; outpatient,
$5700; and non-medical, $488). Family costs averaged $1524/yr
(out of pocket medical and non-medical, $1196; lost salary, $328),
which represented 5% of mean family income. A second US study
compared the costs and health-related quality of life of children
with JIA treated with MTX, etanercept or a combination of the
two agents [7]. A German study evaluated the burden and cost of
illness in JIA but only estimated short-term adult treatment costs
[4]. Haapasaari et al. [6] evaluated the costs of adding etanercept
to existing treatment in Finland.
Unfortunately, these previous JIA costing studies vary greatly
in methodological quality. Many studies report costs only for
individual courses of treatment, report costs in adults only and so
are not relevant to children, or use approximate charge informa-
tion rather than patient-based information. In this study, great
effort was made to use as standardized an approach as possible.
Because of the detailed patient-based data available, we have been
able to identify cost patterns that may not have been apparent if
top-down or other more approximate estimation methods had
been used. A drawback to this study, as in many costing studies,
was the retrospective nature of the cost component of the data
collection, so we had no control over quality of routinely collected
data.
The National Institute for Health and Clinical Excellence
(NICE) has issued clear guidelines on the minimum requirements
for costs that are to be used to inform NHS decision-making
(‘NICE reference case’) [20]. Cost data should have a perspective
that includes both the NHS and personal social services (PSS),
which covers both social work and ‘social care’, services to people
which fall outside the remit of health services. A study evaluating
the specific cost of a hydrotherapy programme in JIA included the
costs of primary care and PSS, as well as time away from work for
parents [3]. Future studies of costing of treatment should consider
all these aspects of JIA management. As we discovered when
deriving our total costs, current reference costs for JIA are not
specific enough to the paediatric status of the patient nor to the
interventions involved in their care.
Our study has presented the costs of 1 yr of treatment and
future analyses will examine costs of longer-term management
after 2 or 3 yrs of treatment. Ongoing developments in treatment
should also be considered. More children are now being treated
with biologic agents such as etanercept. These are more expensive
drugs but may, for example, reduce the incidence of disability and
poor bone health, or cardiac risk from uncontrolled inflammation
and poor physical fitness, thus reducing the overall cost of
management. These longer-term costs and benefits should be
considered in future studies.
This costing study demonstrates the importance of patient-
based cost data to allow characterization of inter-patient
variation. Individual patient costs, or a proxy measure sensitive
to treatment intensity, are required to reflect the wide variation in
cost between patients, and thus allow appropriate recouping of
costs for contracted services and for assessing the economic
impact of interventions. Our study has shown that the key cost-
generating events in the hospital setting in JIA are specialist
referrals. Early input from paediatric rheumatologists is crucial
for these children and may spare them from both unnecessary
invasive investigations, for example, arthroscopy and synovial
biopsy, and also facilitate access to appropriate and prompt
management [21]. In a second analysis of data from 507 children
in CAPS, the median symptom duration at first paediatric
rheumatology assessment was 4.6 months and was shortest for
children presenting with systemic arthritis (1.6 months).
Rheumatology units assessing cost for both practice and research
purposes should concentrate on factors affecting referrals,
admissions, imaging and staff input.
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Rheumatology key messages
 There are few data on the UK costs of treating children with JIA.
 In the first year from diagnosis, children with JIA consume large,
but highly variable, quantities of secondary care health service
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 Costs vary according to JIA subtype.
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